Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

MMWR: Fatal and Severe Hepatitis Associated with Rifampin and Pyrazinamide for the Treatment of Latent Tuberculosis Infection--New York and Georgia, 2000

This report discusses two cases of latent TB infection in which patients developed severe or fatal hepatitis associated with rifampin-pyrazinamide (RIF-PZA) treatment.

Author:

Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, Office of the Morbidity and Mortality Weekly Report Series, CDC MMWR

Topic:

Treatment- Adverse Reactions, Treatment - Latent TB infection (Inactive TB), TB Treatment, Treatment- Medication Information

Country of Origin:

United States

View Webpage

Related Materials

MMWR: Update: Fatal and Severe Liver Injuries Associated With Rifampin and Pyrazinamide for Latent Tuberculosis Infection, and Revisions in American Thoracic Society/CDC Recommendations--United States, 2001

This report provides preliminary information about 21 cases of liver injury associated with rifampin-pyrazinamide (RIF-PZA) and the revised recommendations on selecting appropriate therapy for patients with latent TB infection and monitoring the use of RIF-PZA to treat infection.

Report

Treatment for Latent Tuberculosis (TB) Infection: Rifampin

This handout contains information for patients that are prescribed the 4-month daily regimen of rifampin (4R) for the treatment of latent TB infection. The handout includes space to record the patient's doctor/clinic contact information. 

Brochure

New Treatment Regimen for Latent Tuberculosis Infection

The Communications, Education, and Behavioral Studies Branch (CEBSB) in the Division of Tuberculosis Elimination (DTBE) at CDC developed a video podcast on the 12-dose treatment regimen for latent tuberculosis infection. The video podcast features Dr. Kenneth Castro and is available in English and Spanish. Additional 12-dose regimen communication products are available on the CDC TB Web site (http://www.cdc.gov/tb/).

Webpage

Global resources for the prevention,
management, and elimination of TB.